Impiego del Mydriasert in pazienti da sottoporre ad intervento di cataratta

The preoperative mydriasis is traditionally induced Repeated instillation of phenylephrine and tropicamide. This can give rise to phenomena of accumulation of the active ingredients themselves which, in the channel defluendo naso-lacrimal reaches the systemic circulation, resulting in side effects due to the activity sympathetic mimetic of phenylephrine (hypertension Acute arterial, tachycardia). To avoid instillations ocular repeated but above all to reduce the amount of drugs administered, has been developed MYDRIASERT ®, a new system for slow release of two mydriatics, phenylephrine and tropicamide, content in an insert ocular insoluble, small (4.3 mm x 2.3 mm x 1.6 mm), consisting a central core containing the active principles: the tropicamide (0.28 mg), cycloplegic-mydriatic activities, and phenylephrine hydrochloride (5.4 mg) activities mydriatic. Is externally coated by a membrane dialysis. Once inserted into the lower conjunctival fornix, tears, penetrating into the nucleus, imbibiscono the structure, releasing the active ingredients. The single application, in place of repeated administration mydriatic eye drops, ensures a good compliance. It was therefore conducted a study to assess the systemic effects and to compare the efficacy of mydriasis obtained respectively with the application of the insert and with the instillation of mydriatic eye drops, in two heterogeneous groups of patients undergoing surgery of cataracts. The objective was to evaluate the possibility of obtaining, with the application the insert, a good efficiency and stability of mydriasis induced by a lower release of lower release of drugs